Business
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the release of an abstract on the Co-PSMA (NCT06907641)[1] IIT, accepted for oral presentation at the upcoming EAU Congress 2026, Europe's largest urological conference, to be held from 13 to 16 March 2026 in London, UK[2]. The abstract outlines key findings fro
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"HIGHLIGHTS","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026.","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Co-PSMA IIT evaluated the performance of Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer (with prostate-specific antigen [PSA] 0.2-0.75 ng/mL) following radical prostatectomy who were candidates for curative salvage therapy.","length":364,"tagName":"p"}]},{"val":[{"type":"text","content":"64Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) identified a statistically significant greater number of prostate cancer lesions per patient than 68Ga-PSMA-11 PET/CT (study primary endpoint). The mean per-patient lesion was 1.26 for 64Cu-SAR-bisPSMA vs. 0.48 for 68Ga-PSMA-11, with a difference of 0.78 (95% confidence interval [CI]: 0.52 – 1.04), ratio 2.63 (95%CI: 1.64 – 4.20) (p <0.0001).","length":426,"tagName":"p"}]},{"val":[{"type":"text","content":"In total, 68Ga-PSMA-11 identified 24 lesions across all participants, while 64Cu-SAR-bisPSMA next-day imaging detected 63 lesions.","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"At a per-patient level, 68Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while 64Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"Planned patient management changed following assessment of 64Cu-SAR-bisPSMA PET/CT in 22/50 (44%) trial participants.","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Further data outlining results from the Co-PSMA IIT will be presented at the EAU Congress 2026.","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1629,"olType":false},{"type":"text","content":"SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceutica...